相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Phase I study of 17-allylamino-17 demethoxygeldanamycin, gemcitabine and/or cisplatin in patients with refractory solid tumors
Joleen Hubbard et al.
INVESTIGATIONAL NEW DRUGS (2011)
Shape Effect of Carbon Nanovectors on Angiogenesis
Padmaparna Chaudhuri et al.
ACS NANO (2010)
Epigallocatechin-3-gallate suppresses the expression of HSP70 and HSP90 and exhibits anti-tumor activity in vitro and in vivo
Phan L. C. H. B. Tran et al.
BMC CANCER (2010)
Hyperthermia-associated carboplatin resistance: Differential role of p53, HSF1 and Hsp70 in hepatoma cells
Aanchal Sharma et al.
CANCER SCIENCE (2010)
Heat shock proteins as targets in oncology
Alejandra Gimenez Ortiz et al.
CLINICAL & TRANSLATIONAL ONCOLOGY (2010)
New Molecular and Biological Mechanism of Antitumor Activities of KW-2478, a Novel Nonansamycin Heat Shock Protein 90 Inhibitor, in Multiple Myeloma Cells
Takayuki Nakashima et al.
CLINICAL CANCER RESEARCH (2010)
Synergistic action of the novel HSP90 inhibitor NVP-AUY922 with histone deacetylase inhibitors, melphalan, or doxorubicin in multiple myeloma
Martin Kaiser et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2010)
Novel therapeutic targets for multiple myeloma
Anuj Mahindra et al.
FUTURE ONCOLOGY (2010)
Membrane-bound HSP70-engineered myeloma cell-derived exosomes stimulate more efficient CD8+ CTL- and NK-mediated antitumour immunity than exosomes released from heat-shocked tumour cells expressing cytoplasmic HSP70
Yufeng Xie et al.
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE (2010)
Dual Role of Heat Shock Proteins as Regulators of Apoptosis and Innate Immunity
Anne-Laure Joly et al.
JOURNAL OF INNATE IMMUNITY (2010)
Targeting Hsp90 with small molecule inhibitors induces the over-expression of the anti-apoptotic molecule, survivin, in human A549, HONE-1 and HT-29 cancer cells
Chun Hei Antonio Cheung et al.
MOLECULAR CANCER (2010)
Dual Inhibition of Akt/Mammalian Target of Rapamycin Pathway by Nanoparticle Albumin-Bound-Rapamycin and Perifosine Induces Antitumor Activity in Multiple Myeloma
Diana Cirstea et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Phase I study of the heat shock protein 90 inhibitor alvespimycin (KOS-1022, 17-DMAG) administered intravenously twice weekly to patients with acute myeloid leukemia
J. E. Lancet et al.
LEUKEMIA (2010)
Hsp90: A Drug Target?
Jeffrey M. Holzbeierlein et al.
CURRENT ONCOLOGY REPORTS (2010)
Modulation of Hsf1 activity by novobiocin and geldanamycin
Renaud Conde et al.
BIOCHEMISTRY AND CELL BIOLOGY (2009)
SNX-2112, a selective Hsp90 inhibitor, potently inhibits tumor cell growth, angiogenesis, and osteoclastogenesis in multiple myeloma and other hematologic tumors by abrogating signaling via Akt and ERK
Yutaka Okawa et al.
BLOOD (2009)
Myeloma cell line-derived, pooled heat shock proteins as a universal vaccine for immunotherapy of multiple myeloma
Jianfei Qian et al.
BLOOD (2009)
Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma
Sagar Lonial et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Anti-myeloma activity of the novel 2-aminothienopyrimidine Hsp90 inhibitor NVP-BEP800
Thorsten Stuehmer et al.
BRITISH JOURNAL OF HAEMATOLOGY (2009)
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells
Warren Fiskus et al.
CANCER BIOLOGY & THERAPY (2009)
Future Novel Single Agent and Combination Therapies
Diana Cirstea et al.
CANCER JOURNAL (2009)
Heat Shock Protein 90 Inhibitors: New Mode of Therapy to Overcome Endocrine Resistance
Cynthie Wong et al.
CANCER RESEARCH (2009)
Transcription Inhibition of Heat Shock Proteins: A Strategy for Combination of 17-Allylamino-17-Demethoxygeldanamycin and Actinomycin D
Fabiola Cervantes-Gomez et al.
CANCER RESEARCH (2009)
Targeting CDC37 An alternative, kinase-directed strategy for disruption of oncogenic chaperoning
Jennifer R. Smith et al.
CELL CYCLE (2009)
Heat Shock Protein 90 as a Drug Target: Some Like It Hot
Udai Banerji
CLINICAL CANCER RESEARCH (2009)
17 AAG for HSP90 Inhibition in Cancer - From Bench to Bedside
Saad Z. Usmani et al.
CURRENT MOLECULAR MEDICINE (2009)
Update on Hsp90 Inhibitors in Clinical Trial
Y. S. Kim et al.
CURRENT TOPICS IN MEDICINAL CHEMISTRY (2009)
To fold or not to fold: modulation and consequences of Hsp90 inhibition
Laura B. Peterson et al.
FUTURE MEDICINAL CHEMISTRY (2009)
Targeting Heat Shock Protein 90 with Non-Quinone Inhibitors: A Novel Chemotherapeutic Approach in Human Hepatocellular Carcinoma
Marco Breinig et al.
HEPATOLOGY (2009)
Activation of natural killer cells by heat shock protein 70
Gabriele Multhoff
INTERNATIONAL JOURNAL OF HYPERTHERMIA (2009)
Heat Shock Protein-90 Inhibitors Increase MHC Class I-Related Chain A and B Ligand Expression on Multiple Myeloma Cells and Their Ability to Trigger NK Cell Degranulation
Cinzia Fionda et al.
JOURNAL OF IMMUNOLOGY (2009)
A Cremophor-Free Formulation for Tanespimycin (17-AAG) Using PEO-b-PDLLA Micelles: Characterization and Pharmacokinetics in Rats
May P. Xiong et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2009)
Proteomic and Functional Analyses Reveal a Dual Molecular Mechanism Underlying Arsenic-Induced Apoptosis in Human Multiple Myeloma Cells
Feng Ge et al.
JOURNAL OF PROTEOME RESEARCH (2009)
Bone marrow microenvironment and the identification of new targets for myeloma therapy
K. Podar et al.
LEUKEMIA (2009)
Improved survival of patients with multiple myeloma after the introduction of novel agents and the applicability of the International Staging System (ISS): an analysis of the Greek Myeloma Study Group (GMSG)
E. Kastritis et al.
LEUKEMIA (2009)
A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas
Leandro C. Cerchietti et al.
NATURE MEDICINE (2009)
Silencing the cochaperone CDC37 destabilizes kinase clients and sensitizes cancer cells to HSP90 inhibitors
J. R. Smith et al.
ONCOGENE (2009)
Intravascular Delivery of Particulate Systems: Does Geometry Really Matter?
Paolo Decuzzi et al.
PHARMACEUTICAL RESEARCH (2009)
Trithorax requires Hsp90 for maintenance of active chromatin at sites of gene expression
Muhammad Tariq et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
Emerging Treatments for Multiple Myeloma: Beyond Immunomodulatory Drugs and Bortezomib
Constantine S. Mitsiades et al.
SEMINARS IN HEMATOLOGY (2009)
p38 mitogen-activated protein kinase inhibitor LY2228820 enhances bortezomib-induced cytotoxicity and inhibits osteoclastogenesis in multiple myeloma; therapeutic implications
Kenji Ishitsuka et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
HSP70 inhibition reverses cell adhesion mediated and acquired drug resistance in multiple myeloma
Ramadevi Nimmanapalli et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
A pivotal role for heat shock protein 90 in Ewing Sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment:: in vitro and in vivo study
Ana Sofia Martins et al.
CANCER RESEARCH (2008)
Untangling the unfolded protein response
Emma L. Davenport et al.
CELL CYCLE (2008)
Significance of heat-shock protein (HSP) 90 expression in acute myeloid leukemia cells
Pascale Flandrin et al.
CELL STRESS & CHAPERONES (2008)
New insights into the mechanism of heat shock response activation
I. Shamovsky et al.
CELLULAR AND MOLECULAR LIFE SCIENCES (2008)
SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers
Sarat Chandarlapaty et al.
CLINICAL CANCER RESEARCH (2008)
Targeting Akt and heat shock protein 90 produces synergistic multiple myeloma cell cytotoxicity in the bone marrow microenvironment
Alissa Huston et al.
CLINICAL CANCER RESEARCH (2008)
A Phase 1 Dose-Escalation Study of Irinotecan in Combination with 17-Allylamino-17-Demethoxygeldanamycin in Patients with Solid Tumors
Archie N. Tse et al.
CLINICAL CANCER RESEARCH (2008)
A phase I study of 17-allylamino-17-demethoxygeldanamycin combined with paclitaxel in patients with advanced solid malignancies
Suresh S. Ramalingam et al.
CLINICAL CANCER RESEARCH (2008)
Targeting Hsp90: small-molecule inhibitors and their clinical development
Tony Taldone et al.
CURRENT OPINION IN PHARMACOLOGY (2008)
Development of novobiocin analogues that manifest anti-proliferative activity against several cancer cell lines
Joseph A. Burlison et al.
JOURNAL OF ORGANIC CHEMISTRY (2008)
Telomerase inhibitor GRN163L inhibits myeloma cell growth in vitro and in vivo
M. A. Shammas et al.
LEUKEMIA (2008)
Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
T. Stuehmer et al.
LEUKEMIA (2008)
HSP90/70 chaperones are required for rapid nucleosome removal upon induction of the GAL genes of yeast
Monique Floer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
The effect of particle design on cellular internalization pathways
Stephanie E. A. Gratton et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
IPI-504, a novel and soluble HSP-90 inhibitor, blocks the unfolded protein response in multiple myeloma cells
Jon Patterson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2008)
Improved survival in multiple myeloma and the impact of novel therapies
Shaji K. Kumar et al.
BLOOD (2008)
From the bench to the bedside: emerging new treatments in multiple myeloma
Constantine S. Mitsiades et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2007)
Targeting autophagic regulation of NFκB in HTLV-I transformed cells by geldanamycin -: Implications for therapeutic interventions
Pengrong Yan et al.
AUTOPHAGY (2007)
Intelligent biosynthetic nanobiomaterials for hyperthermic combination chemotherapy and thermal drug targeting of HSP90 inhibitor geldanamycin
Younsoo Bae et al.
JOURNAL OF CONTROLLED RELEASE (2007)
Linking of autophagy to ubiquitin-proteasome system is important for the regulation of endoplasmic reticulum stress and cell viability
Wen-Xing Ding et al.
AMERICAN JOURNAL OF PATHOLOGY (2007)
Inhibition of Hsp90: A multitarget approach to radiosensitization
Kevin Camphausen et al.
CLINICAL CANCER RESEARCH (2007)
Inhibition of heat shock protein 90 prolongs survival of mice with BCR-ABL-T315I-induced leukemia and suppresses leukemic stem cells
Cong Peng et al.
BLOOD (2007)
Bortezomib enhances dendritic cell (DC)-mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells: therapeutic implications
Radek Spisek et al.
BLOOD (2007)
Phase I and pharmacodynamic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with refractory advanced cancers
Ramesh K. Ramanathan et al.
CLINICAL CANCER RESEARCH (2007)
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
David B. Solit et al.
CLINICAL CANCER RESEARCH (2007)
BIRB 796 enhances cytotoxicity triggered by bortezomib, heat shock protein (Hsp) 90 inhibitor, and dexamethasone via inhibition of p38 mitogen-activated protein kinase/Hsp27 pathway in multiple myeloma cell lines and inhibits paracrine tumour growth
Hiroshi Yasui et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
STAT3 and MAPK signaling maintain overexpression of heat shock proteins 90α and β in multiple myeloma cells, which critically contribute to tumor-cell survival
Manik Chatterjee et al.
BLOOD (2007)
Intracellular and extracellular functions of heat shock proteins: repercussions in cancer therapy
E. Schmitt et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2007)
Pathogenesis and molecular targeted therapy of spinal and bulbar muscular atrophy
H. Adachi et al.
NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY (2007)
Combination mammalian target of rapamycin inhibitor rapamycin and HSP90 inhibitor 17-allylamino-17-demethoxygeldanamycin has synergistic activity in multiple myeloma
Lanie K. Francis et al.
CLINICAL CANCER RESEARCH (2006)
Development of 17-allylamino-17-demethoxygeldanamycin hydroquinone hydrochloride (IPI-504), an anti-cancer agent directed against Hsp90
Jens R. Sydor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Hsp90 inhibition results in autophagy-mediated proteasome-independent degradation of IκB kinase (IKK)
Guoliang Qing et al.
CELL RESEARCH (2006)
Endoplasmic reticulum vacuolization and valosin-containing protein relocalization result from simultaneous Hsp90 inhibition by geldanamycin and proteasome inhibition by Velcade
Edward G. Mimnaugh et al.
MOLECULAR CANCER RESEARCH (2006)
Pharmacological induction of Hsp70 protects apoptosis-prone cells from doxorubicin: comparison with caspase-inhibitor- and cycle-arrest-mediated cytoprotection
Z. N. Demidenko et al.
CELL DEATH AND DIFFERENTIATION (2006)
Design, synthesis, and biological evaluation of hydroquinone derivatives of 17-amino-17-demethoxygeldanamycin as potent, water-soluble inhibitors of Hsp90
Jie Ge et al.
JOURNAL OF MEDICINAL CHEMISTRY (2006)
Analysis of expression of heat shock protein-90 (HSP90) and the effects of HSP90 inhibitor (17-AAG) in multiple myeloma
J. Duus et al.
LEUKEMIA & LYMPHOMA (2006)
Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells
Esther A. Obeng et al.
BLOOD (2006)
Synergistic interactions between DMAG and mitogen-activated protein kinase kinase 1/2 inhibitors in Bcr/abl+ leukemia cells sensitive and resistant to imatinib mesylate
TK Nguyen et al.
CLINICAL CANCER RESEARCH (2006)
Inducible heat shock protein 70 expression as a potential predictive marker of metastasis in breast tumors
C Torronteguy et al.
CELL STRESS & CHAPERONES (2006)
Benzoquinone ansamycin heat shock protein 90 inhibitors modulate multiple functions required for tumor angiogenesis
S Sanderson et al.
MOLECULAR CANCER THERAPEUTICS (2006)
Antiapoptotic function of Bcl-2 in mast cells is dependent on its association with heat shock protein 90β
C Cohen-Saidon et al.
BLOOD (2006)
Antimyeloma activity of heat shock protein-90 inhibition
CS Mitsiades et al.
BLOOD (2006)
CCAAT/enhancer binding proteins and interferon signaling pathways
DV Kalvakolanu et al.
JOURNAL OF INTERFERON AND CYTOKINE RESEARCH (2005)
Preclinical toxicity of a geldanamycin analog, 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin (17-DMAG), in rats and dogs: potential clinical relevance
ER Glaze et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
The HSP90 family of genes in the human genome: Insights into their divergence and evolution
B Chen et al.
GENOMICS (2005)
Hsp90α recruited by Sp1 is important for transcription of 12(S)-lipoxygenase in A431 cells
JJ Hung et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
Hsp90 inhibitors identified from a library of novobiocin analogues
XM Yu et al.
JOURNAL OF THE AMERICAN CHEMICAL SOCIETY (2005)
ErbB3 expression predicts tumor cell radiosensitization induced by Hsp90 inhibition
H Dote et al.
CANCER RESEARCH (2005)
Synergistic activity of imatinib and 17-AAG in imatinib-resistant CML cells overexpressing BCR-ABL - Inhibition of P-glycoprotein function by 17-AAG
A Radujkovic et al.
LEUKEMIA (2005)
Phase I pharmacokinetic-pharmacodynamic study of 17-(allylamino)-17-emethoxygeldanamycin (17AAG, NSC 330507), a novel inhibitor of heat shock protein 90, in patients with refractory advanced cancers
RK Ramanathan et al.
CLINICAL CANCER RESEARCH (2005)
Epigallocatechin gallate inhibits aryl hydrocarbon receptor gene transcription through an indirect mechanism involving binding to a 90 kDa heat shock protein
CM Palermo et al.
BIOCHEMISTRY (2005)
Phase I and pharmacologic study of 17-(allylamino)-17-demethoxygeldanamycin in adult patients with solid tumors
JL Grem et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Select forms of tumor cell apoptosis induce dendritic cell maturation
S Demaria et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2005)
Phase I trial of 17-allylamino-17-demethoxygeldanamycin in patients with advanced cancer
MP Goetz et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Combination of the histone deacetylase inhibitor LBH589 and the hsp90 inhibitor 17-AAG is highly active against human CML-BC cells and AML cells with activating mutation of FLT-3
P George et al.
BLOOD (2005)
Hsp90 and Cdc37 - a chaperone cancer conspiracy
LH Pearl
CURRENT OPINION IN GENETICS & DEVELOPMENT (2005)
Mechanistic role of heat shock protein 70 in Bcr-Abl-mediated resistance to apoptosis in human acute leukemia cells
F Guo et al.
BLOOD (2005)
Heat shock protein 90 (Hsp90) chaperone complex inhibitor, Radicicol, potentiated radiation-induced cell killing in a hormone-sensitive prostate cancer cell line through degradation of the androgen receptor
K Harashima et al.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY (2005)
Cellular protein is the source of cross-priming antigen in vivo
LJ Shen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Advances in biology of multiple myeloma: clinical applications
T Hideshima et al.
BLOOD (2004)
Heat shock proteins and their use as anticancer vaccines
G Parmiani et al.
CLINICAL CANCER RESEARCH (2004)
Independent ATPase activity of Hsp90 subunits creates a flexible assembly platform
SH McLaughlin et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
Oncogenic mutations reduce the stability of Src kinase
SF Falsone et al.
JOURNAL OF MOLECULAR BIOLOGY (2004)
CD8+T cell cross-priming via transfer of proteasome substrates
CC Norbury et al.
SCIENCE (2004)
Cell surface expression of an endoplasmic, reticulum resident heat shock protein gp96 triggers MyD88-dependent systemic autoimmune diseases
B Liu et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2003)
Heat-shock proteins as regulators of apoptosis
S Takayama et al.
ONCOGENE (2003)
The Hsp90 chaperone complex as a novel target for cancer therapy
MP Goetz et al.
ANNALS OF ONCOLOGY (2003)
Clinical and cellular pharmacology in relation to solid tumours of childhood
EJ Estlin et al.
CANCER TREATMENT REVIEWS (2003)
Structural and functional analysis of the middle segment of Hsp90: Implications for ATP hydrolysis and client protein and cochaperone interactions
P Meyer et al.
MOLECULAR CELL (2003)
Heat shock protein 90 as a molecular target for cancer therapeutics
JS Isaacs et al.
CANCER CELL (2003)
Disruption of HSP90 function reverts tumor necrosis factor-induced necrosis to apoptosis
T Vanden Berghe et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2003)
The Clinical Applications of Heat Shock Protein Inhibitors in Cancer - Present and Future
Udai Banerji et al.
CURRENT CANCER DRUG TARGETS (2003)
Review of 1027 patients with newly diagnosed multiple myeloma
RA Kyle et al.
MAYO CLINIC PROCEEDINGS (2003)
Molecular sequelae of proteasome inhibition in human multiple myeloma cells
N Mitsiades et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2002)
Hsp90 regulates a von Hippel Lindau-independent hypoxia-inducible factor-1α-degradative pathway
JS Isaacs et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2002)
Disassembly of transcriptional regulatory complexes by molecular chaperones
BC Freeman et al.
SCIENCE (2002)
Heat shock protein 90-antagonist destabilizes Bcr-Abl/HSP90 chaperone complex
Y Shiotsu et al.
LEUKEMIA & LYMPHOMA (2002)
Protein folding - Molecular chaperones in the cytosol: from nascent chain to folded protein
FU Hartl et al.
SCIENCE (2002)
TNF-induced recruitment and activation of the IKK complex require Cdc37 and Hsp90
GQ Chen et al.
MOLECULAR CELL (2002)
HSP90 as a new therapeutic target for cancer therapy: the story unfolds
A Maloney et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2002)
Hsp90 chaperone complexes are required for the activity and stability of yeast protein kinases Mik1, Wee1 and Swe1
FS Goes et al.
EUROPEAN JOURNAL OF BIOCHEMISTRY (2001)
LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing
Y Kabeya et al.
EMBO JOURNAL (2000)
Role of the heat shock response and molecular chaperones in oncogenesis and cell death
C Jolly et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Negative regulation of cytochrome c-mediated oligomerization of Apaf-1 and activation of procaspase-9 by heat shock protein 90
P Pandey et al.
EMBO JOURNAL (2000)
Structure of TPR domain-peptide complexes: Critical elements in the assembly of the Hsp70-Hsp90 multichaperone machine
C Scheufler et al.
CELL (2000)
Novobiocin and related coumarins and depletion of heat shock protein 90-dependent signaling proteins
MG Marcu et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
分享论文
